Former Chief Business Officer · Tracon Pharmaceuticals, Inc. (TCON)

Mark Wiggins

A named executive officer of Tracon Pharmaceuticals in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$495,254

Salary $337,267Stock awards $0

FY2021: $882,568

3rd of 3 named executive officers at Tracon Pharmaceuticals by FY2022 total.

3 named officers on file for Tracon Pharmaceuticals, FY2022

Mark Wiggins’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tracon Pharmaceuticals’s whole pay program stands against its peers

  • Tracon Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCON→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 8, 2023 (DEF 14A).

Free

Get Mark Wiggins’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Wiggins compensation by year

Tracon Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Tracon Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$375,733$337,267
Bonus$0$0
Stock awards$0$0
Option awards$376,316$139,216
Non-equity incentive$118,919$0
Pension and deferred compensation$0$0
All other$11,600$18,771
Total$882,568$495,254

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tracon Pharmaceuticals, Inc. DEF 14A filed March 8, 2023, accession 0001564590-23-003320, and prior-year filings.

How this page was built: the Tracon Pharmaceuticals, Inc. filed document, accession 0001564590-23-003320. Every figure is read from that document and cited to the page and table it appears in. Filed March 8, 2023.

$883K
$495K
FY21
FY22
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option375—$7.90
Option5,959—$4.02
Option28,646—$9.14
Option80,000—$2.32

Per the Outstanding Equity Awards at Fiscal Year-End table in Tracon Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Tracon Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Charles TheuerPresident and Chief Executive Officer$1,264,851
Scott BrownChief Financial Officer$590,860
Mark Wiggins · this pageFormer Chief Business Officer$495,254

The full Tracon Pharmaceuticals compensation record

free company brief

This page is one person within Tracon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tracon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Wiggins's compensation dossier · One-time report. No refunds.